Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immuneering Corporation - Class A Common Stock (NQ: IMRX )

1.520 +0.020 (+1.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immuneering Corporation - Class A Common Stock

< Previous 1 2 3 4 5 Next >
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Immuneering Corporation
Via GlobeNewswire
Maximize Your Trades: Pre-Market Insights And Key Stock Breakdowns
Via Talk Markets
Topics ETFs Stocks / Equities
Why Is Immuneering Stock Trading Higher On Tuesday?
Immuneering reveals promising Phase 2a pancreatic cancer trial updates for IMM-1-104, showcasing efficacy, safety, and future expansion plans. 
Via Benzinga
Why is Immuneering (IMRX) Stock Up 24% Today?
Up nearly 25% in today's session on a fast track designation for a key pancreatic cancer drug candidate, IMRX stock is coming into focus. 
Via InvestorPlace
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
From Immuneering Corporation
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms
From Immuneering Corporation
Via GlobeNewswire
Mastering Market Chaos: StoryTrading’s Top 5 Stocks You Can’t Ignore
The trading landscape is alive with opportunity, shaped by a mix of macroeconomic events and sector-specific moves. 
Via Talk Markets
Topics Stocks / Equities
Immuneering Launches Pancreatic Cancer Advisory Board
From Immuneering Corporation
Via GlobeNewswire
Top Trade Picks Of The Day: Don’t Miss These Market Movers
Discover today’s top stock opportunities with our 4-pillar strategy, combining catalysts, sentiment, fundamentals, and technicals to highlight 6 must-watch trades before the market opens. 
Via Talk Markets
Topics Stocks / Equities
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
From Immuneering Corporation
Via GlobeNewswire
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
Morgan Stanley downgrades Amicus Therapeutics, Immunocore, and Immuneering, citing pricing challenges, pipeline updates, and cautious growth outlooks. 
Via Benzinga
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
From Immuneering Corporation
Via GlobeNewswire
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
A look at the 20 most searched tickers on Benzinga Pro, which includes many familiar names and some penny stocks that may be less familiar. 
Via Benzinga
Why Is Nanocap Immuneering Stock Trading Higher On Friday?
Immuneering reported promising initial response data from its Phase 2a trial for IMM-1-104 combined with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, showing a 40% response rate... 
Via Benzinga
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Nasdaq Surges 1%; Meta Posts Upbeat Earnings
Via Benzinga
Why Carvana Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
From Immuneering Corporation
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Immuneering to Present at the Jefferies Global Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
IMRX Stock Earnings: Immuneering Misses EPS for Q1 2024
IMRX stock results show that Immuneering missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS